CompletedNot Applicable

Ticagrelor Versus Clopidogrel for CMD in Patients With AMI: A Retrospective Study Based on the Angio-IMR

China325 participantsStarted 2017-07-01

Plain-language summary

Coronary microvascular dysfunction (CMD) is increasingly recognized as an important indicator for long-term prognosis in patients with acute myocardial infarction (AMI). The angiography-derived index of microcirculatory resistance (angio-IMR) is a novel guidewire-free measure for CMD in patients with AMI. Ticagrelor has recently been suggested to have additional benefits on coronary microcirculation beyond its antiplatelet effect. This study was designed to compare the protective effects of ticagrelor and clopidogrel on CMD and prognostic impact in patients with AMI, using the angio-IMR as a novel assessment tool.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who were diagnosed with AMI, including STEMI and NSTEMI, and underwent successful PCI and routine follow-up coronary angiography at the Second Affiliated Hospital of Zhejiang University School of Medicine between June 1, 2017 and May 31, 2020. Exclusion Criteria: * 1\) prior treatment with any P2Y12 inhibitor; * 2\) need for long-term oral anticoagulation therapy; * 3\) previous coronary artery bypass grafting (CABG); * 4\) chronic renal dysfunction with estimated glomerular filtration rate (eGFR) \<30 mL/ (min·1.73 m2) or on hemodialysis; * 5\) liver cirrhosis ≥Child-Pugh B class; * 6\) cancer; * 7\) adjustment of dual antiplatelet therapy (DAPT) during follow-up; * 8\) inadequate coronary angiographic images.

What they're measuring

The improvement of angio-IMR

Timeframe: within 24 months post-PCI

Trial details

NCT IDNCT05978726

SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-05-30